Cytori Therapeutics, Inc. CYTX announced top-line data from the SCLERADEC-I study on Cytori Cell Therapy (ECCS-50) that showed sustained benefit at the two-year follow up in patients with hand dysfunction associated with scleroderma.
Results demonstrated statistical improvement in the Cochin Hand Function Score (CHFS), Scleroderma Health Assessment Questionnaire, Raynaud’s Condition Score, and hand pain as assessed by a standard visual analogue scale. Improvements in these end-points were similar to those observed at one year after the treatment of the candidate.
ECCS-50 is also being evaluated in the phase III STAR study and the SCLERADEC-II study for the treatment of patients with scleroderma hand dysfunction. Enrollment of patients is ongoing in both the studies and is expected to be complete in mid-2016.
Meanwhile, Cytori continues to progress with other candidates in its pipeline. Currently, the company is enrolling patients in the phase III ADRESU study for the treatment of patients with stress urinary incontinence. The company expects to finish patient enrollment in 2017.
According to information provided by the company, it is estimated that approximately 100,000 individuals and 50,000 individuals are suffering from scleroderma in the EU and the U.S., respectively.
Cytori currently carries a Zacks Rank #2 (Buy). Other favorably placed stocks in the health care sector include Achillion Pharmaceuticals, Inc. ACHN, Anika Therapeutics Inc. ANIK and Corcept Therapeutics Inc. CORT, each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment